Management of Benign Prostatic Hyperplasia with Metformin, Letrozole and Scheduled Growth Hormone Injections: A Pathophysiology OrientedAbbas Tavakolian Arjmand*
Department of Endocrinology and Metabolic disorders, Shahrood Azad University, Medical School, Shahrood, Iran
- *Corresponding Author:
- Abbas Tavakolian Arjmand
Department of Endocrinology and Metabolic disorders
Shahrood Azad University, Medical School, Shahrood, Iran
E-mail: [email protected]
Received date: June 08, 2017; Accepted date: June 26, 2017; Published date: June 30, 2017
Citation: Abbas Tavakolian Arjmand (2017) Management of Benign Prostatic Hyperplasia with Metformin, Letrozole and Scheduled Growth Hormone Injections: A Pathophysiology Oriented. Epidemiology (Sunnyvale) 7:313. doi:10.4172/2161-1165.1000313
Copyright: © 2017 Arjmand AT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Benign prostatic hyperplasia (BPH) is a common and bothersome condition characterized by prostate overgrowth causing slowly progressive lower urinary tract symptoms. It is highly prevalent in old age, and somewhat inescapable stigma of senility. Due to its major urologic manifestations, BPH has been conventionally assigned as a urologic disorder. Hence, it has remained an orphan medical entity in terms of pathogenesis and management. In fact, BPH, as a true metabolo-proteomic disorder, demands some relevant management strategies. Despite the known impacts of age, inheritance, senile changes in androgen to estrogen ratio, obesity, and metabolic disorders on development of BPH, the core pathogenic mechanisms that logically link and reasonably bring all those scattered findings together has not yet been meaningfully addressed. We believe that almost all informative pieces of BPH pathogenesis have been identified already. Thus, to revolutionize our understanding and to pave a definitely novel path towards medical therapy of BPH with a protocol consisting of metformin, letrozole and scheduled growth hormone injections, we only need to sort the available data out into the jigsaw of BPH pathogenesis picture.